Axovant Sciences Ltd (NASDAQ:AXON) has earned an average recommendation of “Hold” from the fifteen research firms that are covering the firm, MarketBeat.com reports. Four investment analysts have rated the stock with a sell rating, five have assigned a hold rating and six have issued a buy rating on the company. The average 12 month price objective among brokers that have covered the stock in the last year is $13.61.

AXON has been the topic of a number of recent research reports. Oppenheimer reissued a “buy” rating and set a $30.00 target price on shares of Axovant Sciences in a research report on Monday, September 25th. Jefferies Group set a $40.00 target price on shares of Axovant Sciences and gave the stock a “buy” rating in a research report on Friday, August 25th. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price target on shares of Axovant Sciences in a report on Wednesday, September 27th. BidaskClub raised shares of Axovant Sciences from a “sell” rating to a “hold” rating in a report on Thursday, October 5th. Finally, Robert W. Baird reaffirmed a “hold” rating and issued a $6.00 price target on shares of Axovant Sciences in a report on Wednesday, November 1st.

Shares of Axovant Sciences (NASDAQ:AXON) opened at $5.03 on Thursday. The company has a quick ratio of 5.94, a current ratio of 5.94 and a debt-to-equity ratio of 0.34. Axovant Sciences has a 52 week low of $4.60 and a 52 week high of $27.98.

Several institutional investors have recently added to or reduced their stakes in AXON. Oppenheimer & Co. Inc. bought a new position in shares of Axovant Sciences during the third quarter worth about $101,000. Bank of America Corp DE grew its position in shares of Axovant Sciences by 38.9% during the first quarter. Bank of America Corp DE now owns 7,396 shares of the biotechnology company’s stock worth $111,000 after acquiring an additional 2,072 shares during the last quarter. Cubist Systematic Strategies LLC bought a new position in shares of Axovant Sciences during the third quarter worth about $117,000. Legal & General Group Plc grew its position in shares of Axovant Sciences by 20.2% during the second quarter. Legal & General Group Plc now owns 6,955 shares of the biotechnology company’s stock worth $162,000 after acquiring an additional 1,168 shares during the last quarter. Finally, Russell Investments Group Ltd. grew its position in shares of Axovant Sciences by 38.5% during the second quarter. Russell Investments Group Ltd. now owns 10,041 shares of the biotechnology company’s stock worth $233,000 after acquiring an additional 2,789 shares during the last quarter. Institutional investors and hedge funds own 96.93% of the company’s stock.

WARNING: This report was originally posted by American Banking News and is owned by of American Banking News. If you are reading this report on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/12/07/axovant-sciences-ltd-axon-receives-consensus-rating-of-hold-from-analysts-2.html.

Axovant Sciences Company Profile

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Analyst Recommendations for Axovant Sciences (NASDAQ:AXON)

Receive News & Ratings for Axovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd and related companies with MarketBeat.com's FREE daily email newsletter.